EMT-activated secretory and endocytic vesicular trafficking programs underlie a vulnerability to PI4K2A antagonism in lung cancer-Reference-Cited by-同舟云学术

EMT-activated secretory and endocytic vesicular trafficking programs underlie a vulnerability to PI4K2A antagonism in lung cancer

Published:2023-04-03 Issue:7 Volume:133 Page:
ISSN:1558-8238
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:

Author:

Tan Xiaochao^ORCID,Xiao Guan-Yu^ORCID,Wang Shike,Shi Lei^ORCID,Zhao Yanbin,Liu Xin,Yu Jiang,Russell William K.^ORCID,Creighton Chad J.^ORCID,Kurie Jonathan M.

Funder

National Institutes of Health

Lung Cancer Research Foundation

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Link

https://www.jci.org/articles/view/165863/files/pdf

Reference70 articles.

1. The tumor as organizer model

2. p53 loss activates prometastatic secretory vesicle biogenesis in the Golgi

3. PI4KIIIβ is a therapeutic target in chromosome 1q–amplified lung adenocarcinoma

4. PITPNC1 Recruits RAB1B to the Golgi Network to Drive Malignant Secretion

5. A protumorigenic secretory pathway activated by p53 deficiency in lung adenocarcinoma;Tan;J Clin Invest,2021

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The cancer-associated secretory phenotype: a new frontier in targeted therapeutics;Journal of Clinical Investigation;2024-09-03

2. Targeting the secretory program of 3q-amplified lung cancers;Journal of Clinical Investigation;2024-06-17

3. Chromosomal 3q amplicon encodes essential regulators of secretory vesicles that drive secretory addiction in cancer;Journal of Clinical Investigation;2024-04-25

4. PI4K2A: a novel potential therapeutic target for lung cancer;Translational Lung Cancer Research;2024-01

5. An advanced comprehensive muti-cell-type-specific model for predicting anti-PD-1 therapeutic effect in melanoma;Theranostics;2024